Hims Peptides: What the GLP-1 Offering Actually Includes

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This Education Hub article covers GLP-1 therapies, weight management protocols, and the genetic variables shaping metabolic decisions. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Hims or its parent company, and no affiliate links or compensation are involved.

"Peptides" is a broad word, and in the weight-loss telehealth context it usually points to a specific, narrow set of GLP-1 compounds rather than the sprawling world of research peptides. This review clarifies what the term actually covers in a program like Hims and what the offering includes — balanced editorial framing, not a buying recommendation, as of April 2026.

What "peptides" means in a weight-loss context

The peptides at the center of telehealth weight programs are GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide. These are peptide-based medications that act on appetite and glucose pathways. The word "peptides" in this setting is far narrower than its use in general wellness marketing, and reading it precisely avoids confusion.

The GLP-1 peptides at the center of the program

Hims (Hims & Hers Health) operates as subscription telehealth. In this model a licensed provider evaluates the patient virtually, then writes a prescription routed to either a retail pharmacy for FDA-approved brand products or a 503A compounding pharmacy for compounded semaglutide or tirzepatide. The specific peptide compounds offered are shown at intake; confirm the current lineup on Hims's official website.

How a peptide prescription is routed

Across telehealth GLP-1 programs the mechanics are consistent: an intake covering weight, medical history, and medications; a licensed clinician's review and, if eligible, a prescription; fulfillment through retail or 503A compounding pharmacy; and follow-up for titration and side-effect management. Provider type, pharmacy partner, and subscription tier differ between brands.

The trial evidence behind these peptides

The GLP-1 peptides rest on defined trial programs: STEP (semaglutide for weight management, The New England Journal of Medicine, 2021), SURMOUNT (tirzepatide for weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Trial populations and endpoints vary, and individual outcomes vary as well.

The peptide biology genetics maps first

Every peptide in this class acts on a biological system that varies from person to person. MC4R, a melanocortin receptor central to satiety and energy balance, sits with GLP1R (the receptor gene these peptides target), FTO (fat-mass and obesity-associated), and TCF7L2 (tied to glucose homeostasis and GLP-1 secretion). These pathway-level variants do not predict response to any peptide; they describe the terrain a clinician prescribes into.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — including MC4R, GLP1R, FTO, and TCF7L2 variants that shape baseline appetite-regulation and energy-balance biology. That upstream read is the test before you invest approach: informed conversation over guesswork.

Not affiliated: PlexusDx has no affiliation with Hims and no commercial relationship with any company reviewed here.

Related reading on PlexusDx: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1.

Compare the PlexusDx approach: the Weight Management Protocols pair semaglutide and tirzepatide with genetic context, or take the Precision Peptide Genetic Test to map your peptide pathways first.

Frequently Asked Questions

What peptides are involved in a Hims weight program?

In the weight-loss context, "peptides" generally means GLP-1 receptor agonists such as semaglutide and the dual agonist tirzepatide, not the wider category of research peptides. Which specific compound applies, and whether it is branded or compounded, is shown at intake on the brand's own website.

Are these peptides the same as research peptides sold online?

No. The GLP-1 peptides in a legitimate telehealth program are prescription medications dispensed through licensed retail or 503A compounding pharmacies after a clinical evaluation. That is a different pathway from unregulated research peptides, and the distinction matters for safety, sourcing, and clinical oversight.

How does the Precision Peptide Genetic Test relate to these peptides?

It does not predict response to any peptide or program. It reads pathway-level variants in MC4R, GLP1R, FTO, and TCF7L2 that describe your baseline appetite and metabolic biology — upstream context that applies to the GLP-1 peptide class regardless of which service prescribes it.

Where should I confirm the peptide lineup and pricing?

Only on the brand's own website, where compound availability and pricing are published and change over time. Telehealth GLP-1 totals run roughly $200 to $700+ per month as of April 2026 depending on compound, tier, and pathway. Treat third-party figures as unverified until confirmed.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Disclaimer: This article is educational. PlexusDx is not affiliated with Hims and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols; this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.